Passport Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Passport Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,830	Closed	-$247K	–	161
2016 Q3	$247K	Buy	+2,830	New	+$267K	0.01%	131
2014 Q2	–	Sell	-2,872	Closed	-$203K	–	242
2014 Q1	$203K	Buy	+2,872	New	+$227K	0.01%	153

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Passport Capital's VRTX Position: Q4 2016 in Review

Passport Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 2,830 shares — an estimated $247K sold.

Passport Capital first reported a position in VRTX in Q1 2014 and held it in 2 quarters. The position peaked at $247K in Q3 2016. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

Passport Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Passport Capital sold 2,830 Vertex Pharmaceuticals shares in Q4 2016, an estimated $247K.
Passport Capital first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 2 quarters.
Passport Capital's Vertex Pharmaceuticals position peaked at $247K in Q3 2016.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on Passport Capital's 13F filing for Q4 2016, filed 14 Feb 2017.